 This is an open label extension study for patients who participated in placebo-controlled dupilumab atopic dermatitis AD trials. The study primarily evaluates long term safety adverse events and immunogenicity. Efficacy parameters are based on Investigator Global Assessment IGA, Eczema Area and Severity Index EASI and the Pruritus Numerical Rating Scale NRS. 